Vijay Yabannavar - Gritstone Oncology President
President
Dr. Vijay Yabannavar, Ph.D. is Executive Vice President, Manufacturing and Technical Operations of the Company. Dr. Yabannavar joins Gritstone with more than 30 years of process and product development, manufacturing and project leadership experience. As vice president of global technical operations vaccines, biologics and sterile operations at Merck from 2015 until June 2019, he supported a large portfolio of products with total revenues of more than 16 billion per year. Prior to 2015, he was senior vice president of manufacturing technical development at Emergent BioSolutions, and the site head of Emergent Baltimore manufacturing facility with a biodefense focus. From 2007 to 2010, Dr. Yabannavar was vice president of process development and manufacturing at Trubion Pharmaceuticals, where he worked on novel molecules, including bispecifics to treat cancer and autoimmune disorders. Prior to that, he was the head of technical research and development for Novartis Pharmaceuticals, responsible for the process, analytical and formulation development groups for biopharmaceuticals and vaccines since 2019.
| Age | 62 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 510 871 6100 |
| Web | https://gritstonebio.com |
Gritstone Oncology Management Efficiency
The company has return on total asset (ROA) of (0.4671) % which means that it has lost $0.4671 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0194) %, meaning that it created substantial loss on money invested by shareholders. Gritstone Oncology's management efficiency ratios could be used to measure how well Gritstone Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Gritstone Oncology currently holds 104.78 M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest the company is not taking enough advantage from borrowing. Gritstone Oncology has a current ratio of 4.89, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Gritstone Oncology's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 8 records | PRESIDENT Age | ||
| Erik Verner | Corvus Pharmaceuticals | 59 | |
| Thomas Ottoboni | Heron Therapeuti | 65 | |
| David Szekeres | Heron Therapeuti | 50 | |
| William Jones | Corvus Pharmaceuticals | 59 | |
| Jason Fontenot | Sangamo Therapeutics | 54 | |
| Michael Mathews | Heron Therapeuti | 61 | |
| Deborah Knobelman | Kronos Bio | 51 | |
| Sean Ristine | Heron Therapeuti | 55 | |
Management Performance
| Return On Equity | -2.02 | |||
| Return On Asset | -0.47 |
Gritstone Oncology Leadership Team
Elected by the shareholders, the Gritstone Oncology's board of directors comprises two types of representatives: Gritstone Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gritstone. The board's role is to monitor Gritstone Oncology's management team and ensure that shareholders' interests are well served. Gritstone Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gritstone Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vijay Yabannavar, Executive Vice President Manufacturing and Technical Operations | ||
| James Cho, Chief Officer | ||
| Karin Jooss, Executive Vice President - Research, Chief Scientific Officer | ||
| Erin MS, Executive COO | ||
| Dr MBA, Executive Officer | ||
| George MacDougall, Director Communications | ||
| BCh BM, President, CoFounder | ||
| Stacy Proctor, Executive Officer | ||
| Matthew Hawryluk, Executive Vice President Chief Business Officer | ||
| Vassiliki Economides, Executive CFO |
Gritstone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gritstone Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.02 | |||
| Return On Asset | -0.47 | |||
| Operating Margin | (29.95) % | |||
| Current Valuation | 51.54 M | |||
| Shares Outstanding | 118.11 M | |||
| Shares Owned By Insiders | 1.91 % | |||
| Shares Owned By Institutions | 29.03 % | |||
| Number Of Shares Shorted | 7.53 M | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.21 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Gritstone Stock
If you are still planning to invest in Gritstone Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gritstone Oncology's history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |